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Over 95% of the pyridoxal phosphate (PLP) in skeletal muscle is bound to one protein, glycogen phosphorylase. This,
and the fact that phosphorylase constitutes approx. 5 % of the soluble protein in skeletal muscle, introduce the possibility
that PLP might be used as a specific label to identify degradation intermediates of the enzyme. In this investigation, we
have developed immunological methods, using a monoclonal antibody to PLP and polyclonal antibodies to phosphorylase,
to detect degradation intermediates in vitro and in vivo. We have identified a family of degradation intermediates of
glycogen phosphorylase in the high-speed-supernatant fraction of mouse skeletal muscle. These peptides react with both
types of antibodies and are in the size and concentration range expected for degradation intermediates in a model in which
the committed step is followed by ra-pid clearance of the products. Changes in amounts of degradation intermediates are
examined in physiological or pathological conditions in which the rate of degradation of phosphorylase is altered.
INTRODUCTION
Intracellular protein degradation converts a native protein
inta its composite amino acids, and it is implicit that this process
must require the sequential action of proteinases, initially gen-
erating large fragments but eventually yielding free amino acids.
It follows that during the degradative processes intermediates
must be formed by partial proteolysis (Beynon et al., 1985b). In
general, such intermediates have not been observed, implying
that the first, committed, step in intracellular protein catabolism
is considerably slower than subsequent steps (Beynon et al.,
1985 a). The late steps in degradation represent the clearance of
functionally inactivated material and, as such, would be expected
to be rapid. However, many studies in vitro have demonstrated
that proteolytic attack on native proteins can proceed via discrete
transient intermediates that contain relatively resistant domains
(Price & Johnson, 1989). Such investigations establish a precedent
for low concentrations of discrete degradation intermediates
in vivo.
Knowledge of the degradation intermediates could provide
important information on the route(s) of catabolism of an
intracellular protein, identifying proteolytically vulnerable areas
of the molecule. Further, the intracellular localization of these
intermediates would be valuable in identifying the subcellular
sites of early stages of degradation. Identification of degradation
intermediates in vivo is difficult. First, many of the peptides
that are produced are devoid of properties that allow their
identification. Secondly, it is to be expected that these inter-
mediates exist at low levels in the cell, and therefore sensitive
detection methods are needed. Western blots, with antibodies of
the required affinity and selectivity, may provide that sensitivity.
There have been few studies that have attempted to identify
degradation intermediates produced in vivo. The degradation of
biotin-containing enzymes can be monitored with radiolabelled
cofactor, and in cultured cell systems it has proved possible to
demonstrate a family of biotinylated peptides, putatively derived
from these enzymes (Chandler & Ballard, 1988). However, the
four biotin-enzymes are present in cells at similar levels, and it
was not possible to assign the intermediates to one particular
enzyme. Polyclonal antibodies have been used to identify degra-
dation fragments of liver aldolase (Reznick et al., 1985) and
phosphofructokinase (Toda & Ohashi, 1986). The aldolase study
may have been susceptible to degradation artefacts such as we
have described (Cookson & Beynon, 1987), whereas the
phosphofructokinase study used purified enzyme, radilalbelled
in vitro, to demonstrate the lack of artefactual degradation
products.
Glycogen phosphorylase (EC 2.4.1.1; phosphorylase) has a
number ofproperties that facilitate the analysis ofits degradation.
First, it is present at high levels in skeletal muscle, constituting as
much as 5 % of the soluble protein. Second, the enzyme is well
understood in terms of structure (Fletterick & Madsen, 1980;
Dombradi, 1980; Sansom et al., 1985). The three-dimensional
structures of the rabbit phosphorylases a and b are known to less
than 0.3 nm resolution (Sprang & Fletterick, 1979; Sansom et
al., 1985). Finally, over 95 % of the pyridoxal phosphate (PLP)
in skeletal muscle is associated with this enzyme. The cofactor
can therefore be a specific probe for this enzyme, and we have
used radiolabelled PLP to monitor the rate of degradation of the
enzyme (Butler et al., 1985; Cookson & Beynon, 1989). The PLP
is attached to a lysine residue (Lys-680 of a total of 841 amino
acids in the rabbit muscle enzyme) approx. 800% along the
primary sequence, and is buried deep within the phosphorylase
structure. Removal of PLP from the holoenzyme is difficult
(Shaltiel et al., 1967), and thus PLP may remain attached to
degradation intermediates. We have used a monoclonal antibody
to PLP (Viceps-Madore et al., 1983), in combination with
polyclonal antibodies to muscle phosphorylase to search for
degradation intermediates of this enzyme.
MATERIALS AND METHODS
Materials
Pure rabbit skeletal-muscle glycogen phosphorylase was pro-
vided by Professor P. Cohen, University of Dundee. Horseradish
peroxidase-conjugated anti-mouse or anti-rabbit immuno-
globulins were from Dako Ltd., High Wycombe, Bucks., U.K.
Nitrocellulose (pore size 0.2 /tm) was from Schleicher and Schuell,
Abbreviations used: PBS, phosphate-buffered saline (10 mM-sodium phosphate/0. 15 M-NaCl, pH 7.4); PBS-T, PBS containing 0.2% (v/v) Tween
20; PLP, pyridoxal phosphate.
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D-3354 Dassel, West Germany. All other chemicals were of
analytical grade.
Preparation of tissue samples
Adult C57BL/6J and dystrophic C57BL/6JdYIdY mice of either
sex were bred in the Departmental facility. C57BL/1OJ and
dystrophic C57BL/loJmdx/mdx mice were a gift from Dr.
P. McLennan, Department of Medicine, University of Liverpool.
Mice were maintained at 22-25 °C on a 12 h-light/ 12 h-dark
cycle and were allowed free access to food and water. In some
animals, sciatectomy was performed on one hind limb as
described previously (Leyland et al., 1990); the contralateral
limb acted as control. Animals were killed by cervical dislocation,
and liver or skeletal muscle from hind limbs and back was
rapidly dissected and placed on ice. Day-old male broiler chicks
(White Plymouth Rock) were obtained from Vale Royal
Hatcheries, Frodsham, Cheshire, U.K., and 1-day-old male layer
chicks (Hi-Sex Brown) were obtained from Farm Fresh
Hatcheries, Tarleton, Lancashire, U.K. Chickens were housed in
a heated brooder in a room with continuous lighting and were
fed ad libitum on a commercial broiler starter diet containing
19% protein and 10.2 MJ of metabolizable energy/kg. Chickens
(8 weeks old) were killed by cervical dislocation, and the pectoralis
muscle was rapidly dissected and placed on ice. All tissues were
homogenized in 4 vol. of 5 mM-Hepes/l mM-EDTA/14 mM-
mercaptoethanol, pH 7.4 (mouse), or 25 mM-sodium phosphate
buffer, pH 7.4 (chicken), and the homogenate was centrifuged at
50000 g-h. The supernatant fraction was carefully decanted and
was filtered to remove any fat particles.
Antibodies
The monoclonal antibody E6(4)1, highly specific for PLP, was
prepared as described previously (Viceps-Madore et al., 1983).
Ascites fluid was used as a source of IgG without further
purification. Affinity-purified rabbit antibodies to mouse
phosphorylase were prepared as described previously (Cookson
& Beynon, 1987). A polyclonal antibody to pure chicken
phosphorylase was raised in rabbits by an initial subcutaneous
injection of 100 ,ug of chicken phosphorylase, purified to hom-
ogeneity by AMP-Sepharose affinity chromatography, followed
by MonoQ ion-exchange chromatography. The antigen was
injected in Freund's complete adjuvant; subsequently the animal
was boosted by subcutaneous injection at two 6-weekly intervals,
each with 100 #g of protein in Freund's incomplete adjuvant.
PAGE
SDS/PAGE was performed by the method of Studier (1973).
The 1.5 mm-thick gels consisted of a 12.5 % running gel and a
5% stacking gel. Electrophoresis was for 3-4 h at 40 mA at
10 0C. After electrophoresis, parts of the gel were stained for
protein or electroblotted on to nitrocellulose. In some instances,
samples for electrophoresis were treated with 160 mM-NaCNBH3
for 10 min at 4 0C in the presence of 0.25 M-imidazole/citrate
buffer, pH 6.0 (Shaltiel et al., 1967), to reduce and thus to
stabilize the aldimine linkage between cofactor and protein.
Samples were mixed with an equal volume of sample buffer
[0.08 M-Tris/HCl, pH 6.8, containing 20% (w/v) SDS, 0.1 M-
dithiothreitol, 10% (v/v) glycerol and 0.001 0% (w/v)
Bromophenol Blue]. Unreduced samples were treated identically
other than for the omission of NaCNBH3. Samples were kept on
ice, or heated to 60 'C or 100 'C according to the experiment.
Western blotfing
Proteins separated by SDS/PAGE were electroblotted on to
nitrocellulose by a modification of the method of Towbin et al.
(1979). The transfer was performed at 10 °C for 20 h, with a
current of 70 mA. The nitrocellulose membrane was
immunostained with anti-PLP monoclonal antibody or
polyclonal antibodies to mouse or chicken phosphorylase.
All incubations were at room temperature with continuous
shaking. The nitrocellulose was first incubated for 1.5 h in
phosphate-buffered saline (PBS; 10 mM-sodium phosphate/
0.15 M-NaCl, pH 7.4) containing 0.2 % (v/v) Tween 20 (PBS-T)
and a suitable dilution of antibody preparation. The monoclonal
antibody was used at a dilution of ascites fluid of 1:250000, the
rabbit anti-mouse phosphorylase serum at a dilution of 1: 500
and the rabbit anti-chicken phosphorylase serum at a dilution of
1:1000. The nitrocellulose was then washed three times in PBS-
T (5 min/wash). Second antibody, i.e. horseradish peroxidase-
conjugated rabbit anti-mouse immunoglobulin or goat anti-
rabbit immunoglobulin, diluted 1:1000 in PBS-T, was incubated
with the nitrocellulose for 1.5 h, followed by a further three
washes in PBS-T (5 min/wash). Second antibody was detected
by incubating the nitrocellulose for 10 min in PBS-T, containing
0.020% (w/v) diaminobenzidine and 0.03 % (v/v) H202. Faint
degradation products are barely visible when the blot is viewed
in reflected light, and have been emphasized by photography in
transmitted light and by deliberate over-exposure. This treatment
also enhances bands corresponding to non-specific reactions,
which are readily identified by comparison with unreduced
samples.
Limited-proteolysis studies
Pure preparations of rabbit glycogen phosphorylase were
digested with trypsin. At appropriate stages in the digestion the
reaction was terminated by inhibition of the proteinase with
soybean trypsin inhibitor, immobilized on CNBr-activated
Sepharose 6B. The course of the proteolytic reaction was
monitored by measurement of the activity of glycogen
phosphorylase (Carney et al., 1978b) and by densitometric
measurement of the phosphorylase band after SDS/PAGE.
RESULTS AND DISCUSSION
Detection of degradation intermediates
The premises on which our study is based are (a) that limited
proteolysis of phosphorylase generates discrete degradation
intermediates, and (b) that PLP will remain attached to those
intermediates that include the PLP-binding residue. Proteolysis
of native phosphorylase in vitro generates discrete proteolytic
fragments, irrespective of the nature of the proteinase (Raibaud
& Goldberg, 1973; Carney et al., 1978a; Dombradi et al., 1983).
Thus the native protein consists of regions that are vulnerable to
proteolysis, but the products of attack at these sites possess or
acquire a greater resistance to proteolysis, such that intermediates
accumulate. Fig. 1 describes the effect of trypsin on phos-
phorylase. Tryptic attack is much more restricted than would be
expected from the primary specificity of this proteinase. Several
degradation products of 50-90 kDa are generated, but none of
them retain glycogenolytic activity, as the pseudo-first-order rate
constant for inactivation of phosphorylase was 0.023 min-',
which compares with a value of 0.024 min-' for the loss of
97.4 kDa phosphorylase band on SDS/PAGE. There are no
intermediates between 40 kDa and low-molecular-mass peptidic
material (< 5 kDa) at the bottom of the gel, which implies that
material smaller than 40 kDa has lost sufficient higher-order
structure to become vulnerable to rapid and extensive proteolysis.
The family of degradation intermediates generated by trypsin
has been used as a model system for this study.
PLP does not remain attached to proteins under the denaturing
conditions of sample preparation for SDS/PAGE, and it is
necessary to reduce the Schiff base between the aldehyde group
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Fig. 2. Immunological detection of degradation






Rabbit muscle glycogen phosphorylase (2.0 mg/ml) was digested for
140 min at 30 °C with trypsin (30,g/ml) in 0.02 M-Hepes buffer,
pH 7.4, containing 0.1 M-Na2SO4. The digest was split into two, and
one half was treated with NaCNBH3 (+ [H]) as described in the
Materials and methods section before SDS/PAGE. Identical pairs
of lanes (one reduced sample, + [H]; one unreduced sample, - [H])
were either stained for protein in the gel or electroblotted on to
nitrocellulose. Of the latter, one pair was probed with a polyclonal
antibody to phosphorylase, and the other with a monoclonal
antibody to PLP.
Fig. 1. Generation of degradation intermediates by proteolysis of
phosphorylase in vitro
Rabbit muscle glycogen phosphorylase (1.2 mg/ml) was digested at
30 °C with trypsin (5 ,ug/ml) in 0.02 M-Hepes buffer, pH 7.4, con-
taining 0.1 M-Na2SOV At suitable time intervals, samples were
removed for assay of phosphorylase activity ([O). At the same time
a further sample (60 #1) was added to 40 mg of soybean trypsin
inhibitor-Sepharose 6B (equivalent to 100lOg of inhibitor). The
mixture was centrifuged, and the supernatant (10 jug of protein) was
subjected to SDS/PAGE. The gel was stained for protein (lower
panel) and the phosphorylase band (-, 97 kDa) in each lane was
quantified by densitometry.
on the cofactor and the e-amino group on the protein. Extended
treatment of phosphorylase with reducing agents such as NaBH4
elicits low-level fragmentation of the protein. Preliminary
experiments established that treatment with 160 mM-NaCNBH3
for 10 min gave substantial fixation of cofactor without
artefactual fragmentation. In this respect NaCNBH3 is superior
to the more reactive NaBH4. When phosphorylase is treated with
either NaBH4 or NaCNBH3, the apparent molecular mass on
SDS/PAGE increases (Fig. 2). We have no explanation for this
phenomenon, although retention of cofactor on the protein may
interfere with SDS binding. The shift in mobility seems to be
specific to phosphorylase (and has been observed with rabbit,
mouse and chicken enzymes), and is a useful diagnostic tool for
the identification of the protein and PLP-containing fragments.
Retention of PLP by degradation fragments
Detection of phosphorylase-derived peptides by the anti-PLP
monoclonal antibody is only feasible if the cofactor remains
attached to the products of proteolysis. A tryptic digest of
phosphorylase (< 10% residual activity) was monitored by Fast
Green staining of protein bands in the polyacrylamide gel and by
Western blots (Fig. 2), either with an affinity-purified polyclonal
antibody to mouse phosphorylase ('anti-phosphorylase'), or
with a monoclonal antibody to PLP ('anti-PLP'). All tryptic
peptides can be detected by the polyclonal antibody to the
protein. After NaCNBH3 treatment most of the bands increase
in mobility. Moreover, anti-PLP Western blotting demonstrates
that many of these degradation intermediates contain PLP. The
specificity of the monoclonal antibody is confirmed by the lane
in which a sample was electrophoresed without reduction with
NaCNBH3; no bands are visible. Some bands react with anti-
phosphorylase, but do not react with anti-PLP; these are peptides
that have lost cofactor or which do not include the PLP-binding
lysine. All peptides of molecular mass greater than about 78 kDa
must contain the PLP-binding residue, and, as expected, peptides
unreactive with the anti-PLP monoclonal antibody are all smaller
than this. Fig. 2 also demonstrates the greater sensitivity of the
anti-PLP antibody relative to the polyclonal antibody to the
protein.
PLP remains attached to phosphorylase degradation products
during proteolysis in vitro, and can be detected with the sensitivity
and selectivity that might be applicable to studies of the degra-
dation of the enzyme in vivo. However, the time scale of the
proteolysis experiments in vitro is dramatically shorter (first-
order rate constant for inactivation = 1.38 h-') than the time
frame for degradation of the enzyme in vivo. The first-order rate
constant for phosphorylase degradation in mouse skeletal muscle
is approx. 0.1 day-1 (Cookson & Beynon, 1989; Leyland et al.,
1990; Leyland & Beynon, 1991). It was therefore necessary to
examine the stability of the PLP-peptide linkage over a longer
period. A tryptic digest of phosphorylase was treated with an
excess of immobilized soybean trypsin inhibitor to remove the
proteinase, and the peptide mixture was dialysed for 72 h against
PBS containing a strong PLP-scavenging reagent (10 mm-
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Fig. 3. PLP-binding proteins in soluble fractions of mouse skeletal muscle
and liver
Skeletal muscle or liver was homogenized in 4 vol. of 20 mm-
Hepes/O. 14 m-NaCI, pH 7.4. The homogenate was centrifuged at
00000 g h and a portion of each supematant fraction was treated
with NaCNBH3 (+ [H]). Reduced and unreduced (-[H]) samples
(liver 60 jig of protein; muscle 45 /sg of protein) were separated by
SDS/PAGE, and the gel was stained for protein or electroblotted on
to nitrocellulose and probed with monoclonal anti-PLP antibody.
solved on SDS/PAGE and stained for protein, or immunoblotted
with the anti-PLP monoclonal antibody. After exhaustive dialysis
against hydroxylamine there was no further proteolytic digestion
of phosphorylase, and PLP was still attached to phosphorylase
and its degradation products (results not shown). Thus, degra-
dation products possess sufficient higher-order structure to retain
PLP even in the presence of a reagent that promotes dissociation.
The requirement for higher-order structure was confirmed by
dialysis against the same buffer containing 0.1 % (w/v) SDS;
PLP was lost from all peptides (results not shown).
Specificity of labelling of phosphorylase in vivo by PLP
PLP-labelled degradation intermediates of phosphorylase
would be observed against a background of bands attributed to
other PLP-binding proteins present in the tissue preparations.
Thus the size distribution of PLP-containing proteins in vivo was
assessed in liver and skeletal muscle, the two largest pools of PLP
in the body. Soluble proteins from both tissues were prepared,
immediately treated with NaCNBH3, separated by SDS/PAGE
and blotted with the monoclonal antibody to PLP (Fig. 3). Some
non-specific binding of the antibody is seen both in liver and
muscle preparations, but this is identifiable by the duplication of
the bands in lanes that have not been treated with NaCNBH3.
Comparison of NaCNBH3-reduced samples with unreduced
samples is a useful control that identifies non-specific bands on
Western blots. Phosphorylase is not a major PLP-binding protein
in liver, and the region of the blot in which degradation fragments
would be expected is occupied by many other bands, attributable
to both specific and non-specific effects. This contrasts with
skeletal muscle, in which the great majority of PLP is bound to
glycogen phosphorylase. In muscle preparations, some PLP-
proteins were identified at the lower molecular mass of
40-45 kDa; these are putatively aminotransferases.
PLP-labelled degradation intermediates of phosphorylase in
skeletal muscle
In some blots, faint PLP-containing bands (for example, at
approx. 70 kDa) could be seen (results not shown). These could
be the products of intracellular degradation of phosphorylase.
However, the heating of samples during preparation for
SDS/PAGE can cause low-level fragmentation of proteins, the
products of which might be misconstrued as products of
proteolysis in vivo (Cookson & Beynon, 1987). Accordingly, a
muscle supernatant was exposed to different temperatures, and
for various times, during sample preparation for SDS/PAGE
(Fig. 4a). Incubation at 100 °C caused detectable fragmentation
of phosphorylase, resulting in the progressive appearance of
bands on the Western blot using anti-PLP (extreme right-hand
lane of Fig. 4a). At 60 °C these PLP-peptides are not generated,
but several bands in the 40-90 kDa range decrease in intensity
during incubation at 60 'C. When a muscle supernatant fraction
was treated with sample buffer at 4 'C and loaded at room
temperature, the same peptides were present at higher
concentrations and are therefore heat-labile. Although the non-
specific staining is worse in the absence of heat treatment, there
was clear evidence of one strongly staining band of the same
mobility as that seen at 60 'C (see lower arrow on Fig. 4a), and
a number of other faint bands that we believe are present in
skeletal muscle in vivo. These PLP-containing bands are also
visible on blots probed with affinity-purified anti-phosphorylase
IgG and elicit the same response on heating (Fig. 4b), which
confirms that they are derived from phosphorylase in vivo. The
anti-phosphorylase IgG also identifies bands on both NaCNBH3-
treated and untreated samples, and these show the shift in
mobility on reduction that is consistent with their derivation
from phosphorylase.
These putative degradation intermediates are all in the range
60-70 kDa, although the NaCNBH3-induced shift in mobility
precludes accurate estimates of size. These must be resistant
phosphorylase fragments that retain sufficient structure to bind
cofactor, and to survive in muscle. Proteolysis of phosphorylase
in vivo yields fragments of the same sizes as are seen in vitro with
purified proteinases, and it is likely that there are regions of the
phosphorylase molecule that are susceptible to proteolytic attack,
irrespective of the nature of the proteinase. These fragments, in
common with phosphorylase, were only present in the muscle
high-speed supernatant fraction. No other PLP-labelled peptides
were! detectable in either homogenates or sedimented fractions
(E. J. Cookson, unpublished work).
Degradation intermediates in different muscle systems
The levels and pattern of degradation intermediates were
assessed under a number of different conditions in which we have
shown that the rate of degradation of phosphorylase is altered.
The steady-state levels of intermediates reflect the relative ac-
tivities of the proteolytic processes that are responsible for both
their generation and removal. Additionally, new degradation
products might imply the activity of a previously inactive
proteolytic system. We have previously measured the rate of
degradation of phosphorylase in normal and dystrophic
(C57BL/6JdY/dY) mouse skeletal muscle. In normal muscle, the
rate of degradation of the enzyme in C57BL/6J mouse muscle is
0.125 day-', but is lower (0.049 day-') in C57BL/6JdY/dY mice





Degradation intermediates of glycogen phosphorylase
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Fig. 4. Genuine and artefactual degradation intermediates of glycogen phosphorylase
Freshly prepared mouse muscle supernatant fraction (a portion of which was treated with NaCNBH3; + [H]) was heated for the indicated
time/temperature in SDS/PAGE sample buffer before SDS/PAGE. (a) The gel was electroblotted on to nitrocellulose and probed with
monoclonal anti-PLP antibody. The sample labelled '25 °C' was left at room temperature for 20 min. Each lane contains 80 ,sg of protein. The
top arrow identifies the strongly stained phosphorylase band (although, because of the NaCNBH3 treatment, not at 97.4 kDa); the bottom arrow
identifies the main degradation intermediate. (b) The gel was electroblotted on to nitrocellulose, and identical lanes were probed with a monoclonal
antibody to PLP (Anti-PLP) and a polyclonal antibody to glycogen phosphorylase (Anti-ph.). The arrowhead (<) identifies the main degradation
intermediate (that shifts on the gel after NaCNBH3 treatment).
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Fig. 5. Degradation intermediates of glycogen phosphorylase during
denervation-induced muscle atrophy
Muscle samples from the gastrocnemius of control and 10-, 20- and
30-day left-sciatectomized mice were treated (with and without
reduction by NaCNBH3; + [H] and -[H] respectively) as described
in the Materials and methods section and Western-blotted with a
monoclonal antibody to PLP. Degradation intermediates are
identified by arrowheads.
dramatically decreased, and thus the lower amount of phos-
phorylase in dystrophic muscle is attributable to generalized
down-regulation of enzyme turnover. The pattern and level of
degradation intermediates were the same in C57BL/6J and
C57BL/6JdY/dY mice. Further, there was no difference in pattern
between the C57BL/1OJ and the dystrophin-deficient
C57BL/lOmdx/mdx dystrophic mouse, in which the levels of
phosphorylase are unaltered (A. V. Flannery, unpublished
work). There is no evidence for alterations in the pattern of
protein degradation in the two dystrophic phenotypes.
After section of the sciatic nerve in the mouse there is a marked
wasting of the lower hind-limb muscles, and the specific activity
of phosphorylase falls to approx. 300% of that of the contra-
lateral control limb, which does not change. The decrease in
phosphorylase content in the muscle is attributable in part to an
accelerated degradation of the enzyme, from 0.12 to 0.20 day-1
(Leyland et al., 1990). Degradation intermediates were deter-
mined in muscle at 10, 20 and 30 days after denervation. At these
times, the phosphorylase activity as a percentage of that of the
contralateral limb was 49 %, 30% and 15 % respectively. There
are no changes in phosphorylase expression in the contralateral
limb over this period (Leyland et al., 1990). At 10 days after
denervation, the degradation intermediates were present in
muscle at a higher concentration, but were of the same sizes as
those in normal muscle (Fig. 5). This implies that the accelerated
removal of phosphorylase from denervated muscle is due to an
increase in the activity of the sa-me degradative machinery that
operates in normal muscle. Denervation-induced atrophy induces
multiple proteolytic systems, and Furuno et al. (1990) have
suggested that the degradation of cytosolic proteins in skeletal
muscle is largely attributable to a non-lysosomal proteolytic
system. This is consistent with our observation that there are no
phosphorylase degradation intermediates in the particulate frac-
tion ofmouse skeletal muscle (E. J. Cookson, unpublished work).
At 20 and 30 days after denervation, the levels of intermediates
are much lower, consistent with the lower amount of
phosphorylase in the muscle and a higher rate of degradation,
which would combine to decrease the pool size of degradation
fragments.
We have recently measured, by PLP-labelling, the rate of
degradation of phosphorylase in the pectoralis muscle of broiler
and layer chickens (Flannery et al., 1992). This muscle grows
extremely rapidly in broiler chickens, and over a 5-week period
(from 3 to 8 weeks of age) the total pectoralis content of glycogen
phosphorylase increases by 18-fold, from approx. 75 to 1400 mg.
By contrast, in layer chickens, the same pool expands by 3-fold
from approx. 100 to 270 mg over the same period. The major
influence on accumulation of enzyme is the rate of synthesis, but
the rate of degradation of the enzyme in 8-week-old animals in
broilers is approximately twice that in layers. Accordingly, we
examined the degradation intermediates in broiler and layer
pectoralis muscle, using anti-PLP and a polyclonal antibody to
chicken phosphorylase. Intermediates, similar to those seen in
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Fig. 6. Degradation intermediates of glycogen phosphorylase in the
pectoralis muscle of broiler and layer chickens
Pectoralis muscle from 8-week-old broiler and layer chickens was
used to prepare a supernatant fraction as described in the Materials
and methods section. A portion of this supernatant was treated with
NaCNBH3 (' + [H]') and kept at 25 °C before SDS/PAGE. The gel
was electroblotted on to nitrocellulose, and identical lanes were
probed with a monoclonal antibody to PLP (Anti-PLP) and a
polyclonal antibody to chicken glycogen phosphorylase (Anti-
phosphorylase). Degradation intermediates are identified by
arrowheads.
confirmatory shift in mobility on NaCNBH3 reduction, a feature
of all animal phosphorylases that we have examined, is also
evident for these samples when blotted with the anti-
phosphorylase serum. The pattern of intermediates, which was
essentially the same in broiler and layer muscle, implies that
alterations in the rate of degradation of phosphorylase are
elicited by changes in the activity of existing degradative
processes, rather than by activation or suppression of complete
systems. There were no obvious differences in the relative
amounts of the intermediates in the muscle from the two strains.
The levels of these degradation products are very low. In
isolated cells they can be increased by inclusion of proteinase
inhibitors or lysosomotropic agents in media (Botbol & Scornick,
1983). Such manipulations are not possible in intact animals, and
we estimate that in vivo the levels of phosphorylase-derived
intermediates are substantially less than 1% of the amount of
intact protein. This has implications for the degradation kinetics
of the enzyme, and reinforces the concept of a 'committed
step' that is followed by rapid clearance of the committed
protein molecule. It has been suggested that the multi-catalytic
proteinase, or proteasome, may act by co-operativity between
individual catalytic subunits, and that this might confer a degree
of 'processivity' on proteolysis which might lead to degradation
that was essentially complete after the protein was committed to
destruction (Dick et al., 1991). At present, we have no knowledge
of the nature of the committed step for phosphorylase,
which might include limited proteolysis, ubiquitin-mediated
conjugation/proteolysis, release from a glycogen particle or
sequestration into a different subcellular-compartment. However,
irrespective of the nature of this step, it is apparent that the
products, including the 70 kDa peptide(s), are removed from the
muscle cell at a rate constant that could be at least two orders of
magnitude greater than the rate of degradation. Although this is
expected on teleological grounds, the mechanism whereby a
protein can be committed slowly to a very rapid process remains
unclear, but is one of the keys to an understanding of protein
degradation.
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